康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09926 康方生物

交易中 07-03 11:52:01

37.500

+0.350

+0.94%

最高37.500	最低36.400	成交量171.50万
今开36.900	昨收37.150	日振幅2.96%
总市值324.70亿	流通市值324.70亿	总股本8.66亿
成交额6,330万	换手率0.20%	流通股本8.66亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09926","market":"HK","secType":"STK","nameCN":"康方生物","latestPrice":37.5,"timestamp":1719978702167,"preClose":37.15,"halted":0,"volume":1715000,"delay":0,"floatShares":865857176,"shares":865857176,"eps":2.5880737,"marketStatus":"交易中","marketStatusCode":2,"change":0.35,"latestTime":"07-03 11:52:01","open":36.9,"high":37.5,"low":36.4,"amount":63295850,"amplitude":0.02961,"askPrice":37.5,"askSize":59000,"bidPrice":37.4,"bidSize":33000,"shortable":3,"etf":0,"ttmEps":2.5866627331244723,"exchange":"SEHK","tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1719979200000},"adr":0,"listingDate":1587657600000,"adjPreClose":37.15,"openAndCloseTimeList":[[1719970200000,1719979200000],[1719982800000,1719993600000]],"volumeRatio":0.867009,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09926","defaultTab":"news","newsList":[{"id":"2448099600","title":"康方生物(09926)：张鹏获委任为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2448099600","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448099600?lang=zh_cn&edition=full","pubTime":"2024-07-01 19:42","pubTimestamp":1719834136,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康方生物(09926)发布公告，自2024年6月30日起：夏羽先生(博士)辞任执行董事;周伊博士辞任非执行董事;及张鹏博士获委任为执行董事。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348784397.USD","09926","LU0348783233.USD","LU1720050803.USD","LU1794554557.SGD","IE00B543WZ88.USD","LU0417516571.SGD","BK1574","IE00B5MMRT66.SGD","BK1161"],"gpt_icon":0},{"id":"2448028993","title":"康方生物(09926.HK)委任张鹏为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2448028993","media":"格隆汇资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448028993?lang=zh_cn&edition=full","pubTime":"2024-07-01 19:04","pubTimestamp":1719831866,"startTime":"0","endTime":"0","summary":"格隆汇7月1日丨康方生物(09926.HK)宣布，自2024年6月30日起，夏羽辞任执行董事，周伊辞任非执行董事，张鹏获委任为执行董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240701190523955e99c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240701190523955e99c1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B543WZ88.USD","LU1794554557.SGD","LU0417516571.SGD","BK1161","LU1720050803.USD","IE00B5MMRT66.SGD","LU0348784397.USD","BK1574","LU0348783233.USD","09926"],"gpt_icon":0},{"id":"2448312009","title":"中泰证券：关注Q2业绩超预期 把握医药底部资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2448312009","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448312009?lang=zh_cn&edition=full","pubTime":"2024-07-01 10:36","pubTimestamp":1719801388,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中泰证券发布研报称，展望下半年，行业基本面有望从24Q3开始改善，低基数下业绩增速有望逐季回升，政策层面创新药支持政策、医疗反腐等均有望边际向好，医药板块有望迎来一波强势反弹，建议当下提前布局底部有弹性的资产。本月所有子板块均有所下跌，其中医疗器械跌幅最小，下跌7.03%，医药商业跌幅最大，下跌17.27%。展望7月：关注Q2业绩超预期，把握医药底部资产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09926","IE00B543WZ88.USD","159938","IE00B5MMRT66.SGD","BK1515","LU0348784397.USD","LU1720050803.USD","LU1794554557.SGD","09939","LU0417516571.SGD","LU0348783233.USD","BK1574","600918","BK0276"],"gpt_icon":0},{"id":"2446330791","title":"【券商聚焦】华泰证券维持康方生物(09926)“买入”评级 依沃西单抗获批料将助其向大药企转型","url":"https://stock-news.laohu8.com/highlight/detail?id=2446330791","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446330791?lang=zh_cn&edition=full","pubTime":"2024-06-26 15:30","pubTimestamp":1719387054,"startTime":"0","endTime":"0","summary":"金吾财讯 | 华泰证券发研指，近日，康方生物 连续披露两项PD-1/VEGFR双抗依沃西单抗的III期临床结果，在PD-L1 TPS ≥ 1%的 NSCLC患者中头对头击败帕博利珠单抗、和在EGFR-TKI耐药NSCLC患者中取得PFS7.1vs4.8月的显著获益。依沃西单抗于5月24日在国内获批上市，该行预计其国内峰值销售额71亿元。依沃西单抗在HARMONi-2研究的中期分析中头对头击败当前肺癌免疫治疗“王者”帕博利珠单抗的阳性结果证实了其临床价值。","market":"sh","thumbnail":"https://static.szfiu.com/news/20210810/ZDcxODE0MDcxNDc0MDg4MTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDcxODE0MDcxNDc0MDg4MTY=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1939355","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"gpt_icon":0},{"id":"2446588163","title":"康方生物(09926)上涨5.1%，报40.2元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446588163","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446588163?lang=zh_cn&edition=full","pubTime":"2024-06-26 15:27","pubTimestamp":1719386855,"startTime":"0","endTime":"0","summary":"6月26日，康方生物盘中上涨5.1%，截至15:27，报40.2元/股，成交1.76亿元。康方生物科技(开曼)有限公司是一家专注于研究、开发、生产和商业化全球病人可负担的创新抗体新药的生物制药公司，拥有独特的研发创新体系、国际化标准的GMP生产体系和先进的商业化体系。截至2023年年报，康方生物营业总收入45.26亿元、净利润20.28亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/26152741209507.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0417516571.SGD","IE00B5MMRT66.SGD","LU1720050803.USD","BK1161","IE00B543WZ88.USD","LU0348783233.USD","LU0348784397.USD","BK1574","LU1794554557.SGD","09926"],"gpt_icon":0},{"id":"2446330870","title":"康方生物盘中异动 下午盘股价大涨5.10%报40.201港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2446330870","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446330870?lang=zh_cn&edition=full","pubTime":"2024-06-26 15:27","pubTimestamp":1719386852,"startTime":"0","endTime":"0","summary":"2024年06月26日下午盘15时27分，康方生物股票出现异动，股价大幅拉升5.10%。截至发稿，该股报40.201港元/股，成交量445.071万股，换手率0.51%，振幅6.27%。资金方面，该股资金流入1.00087亿港元，流出5602.8万港元。康方生物股票所在的生物技术行业中，整体跌幅为0.34%。消息层面，截至15时27分，康方生物股票正面舆情新闻比例12.5%。依沃西单抗于5 月24 日在国内获批上市，我们预计其国内峰值销售额71 亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240626152732941f15b0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240626152732941f15b0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348784397.USD","LU1720050803.USD","LU0348783233.USD","LU0417516571.SGD","BK1574","LU1794554557.SGD","09926","BK1161","IE00B543WZ88.USD","IE00B5MMRT66.SGD"],"gpt_icon":0},{"id":"2446033452","title":"康方生物(9926.HK)：决胜肺癌 依沃西单抗带来新曙光","url":"https://stock-news.laohu8.com/highlight/detail?id=2446033452","media":"华泰证券","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446033452?lang=zh_cn&edition=full","pubTime":"2024-06-26 14:21","pubTimestamp":1719382904,"startTime":"0","endTime":"0","summary":"依沃西单抗获得两大临床阳性结果，维持公司“买入”评级近日，公司连续披露两项PD-1/VEGFR 双抗依沃西单抗的III 期临床结果，在PD-L1 TPS ≥ 1%的NSCLC 患者中头对头击败帕博利珠单抗、和在EGFR-TKI 耐药NSCLC患者中取得PFS 7.1 vs 4.8 月的显著获益。依沃西单抗于5 月24 日在国内获批上市，我们预计其国内峰值销售额71 亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261421469f669a4f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261421469f669a4f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1720050803.USD","LU0348784397.USD","IE00B5MMRT66.SGD","LU1794554557.SGD","BK1161","09926","LU0417516571.SGD","IE00B543WZ88.USD","LU0348783233.USD","BK1574"],"gpt_icon":0},{"id":"2446351613","title":"港股异动 | 康方生物(09926)午后涨超3% 卡度尼利单抗降价 公司表示将参加今年国谈","url":"https://stock-news.laohu8.com/highlight/detail?id=2446351613","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446351613?lang=zh_cn&edition=full","pubTime":"2024-06-26 13:39","pubTimestamp":1719380393,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物午后涨超3%，截至发稿，跌3.01%，报39.4港元，成交额8829.33万港元。此外，据行业媒体医药魔方的报道，2024年国家医保谈判进入准备阶段之际，康方生物下调了其双抗新药卡度尼利单抗的价格。同日，康方生物向界面新闻确认了这一价格且取消赠药，称这一价格将给予患者购药更大灵活性，并表示将积极参加今年医保谈判。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140656.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0348783233.USD","HSCEI","07226","YANG","BK1574","LU0417516571.SGD","BK1161","HSTECH","IE00B5MMRT66.SGD","LU0348784397.USD","IE00B543WZ88.USD","LU1720050803.USD","LU1794554557.SGD","09926"],"gpt_icon":0},{"id":"2446813440","title":"多领域展现巨大应用潜力 双抗药物进入“寻宝”竞速赛","url":"https://stock-news.laohu8.com/highlight/detail?id=2446813440","media":"第一财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446813440?lang=zh_cn&edition=full","pubTime":"2024-06-25 18:04","pubTimestamp":1719309866,"startTime":"0","endTime":"0","summary":"在上月召开的ASCO2024会议上，多家中国创新药企披露了在研双抗药物的临床数据，其中，康方生物（09926.HK）披露其已上市的双抗药物依沃西在对比K药一线治疗PD-L1表达阳性的局部晚期或转移性非小细胞肺癌的III期临床试验中，呈现出显著优于后者的疗效，成为全球首款在III期单药头对头临床试验中击败K药的创新药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202406253113233195.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202406253113233195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999001176.USD","SG9999014559.SGD","BK1515","SG9999014567.USD","MRK","09926","LU0861579265.USD","LU1720050803.USD","BK4585","IE00BFTCPJ56.SGD","SG9999002232.USD","BK4588","LU1989771016.USD","SG9999001176.SGD","L","LU1989772923.USD","IE0002141913.USD","LU2461242641.AUD","LU0348784397.USD","IE0009355771.USD","LU1093756325.SGD","09966","LU0058720904.USD","01177","SG9999002224.SGD","LU0417516571.SGD","LU2361044949.HKD","IE00BJJMRZ35.SGD","LU0320765489.SGD","BK4559","IE00BJT1NW94.SGD","LU2361045086.USD","BK4516","BK1589","LU1066051498.USD","IE00B1BXHZ80.USD","LU0211331839.USD","LU0053666078.USD","LU2361044865.SGD","BK1161","BK1191","BK4533","LU0122379950.USD","LU1989772840.SGD","IE00BBT3K403.USD","BK4550","LU1917777945.USD","LU2023250504.SGD","LU1066053197.SGD","BK4007"],"gpt_icon":0},{"id":"2446858869","title":"康方生物6月24日遭南向资金减持137.50万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446858869","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446858869?lang=zh_cn&edition=full","pubTime":"2024-06-25 09:31","pubTimestamp":1719279100,"startTime":"0","endTime":"0","summary":"6月24日，南向资金减持康方生物137.50万股。截止当日收盘，港股通共持有康方生物31364.72万股，占流通股36.21%。康方生物近5个交易日下跌6.37%，港股通累计减持20.38万股；近20个交易日上涨3.10%，港股通累计增持1977.80万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062509421695d49b9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062509421695d49b9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B5MMRT66.SGD","LU0348784397.USD","LU1720050803.USD","BK1161","LU0348783233.USD","LU1794554557.SGD","IE00B543WZ88.USD","LU0417516571.SGD","BK1574","09926"],"gpt_icon":0},{"id":"2445204237","title":"【券商聚焦】中泰证券首予康方生物(09926)“买入”评级 指其抗肿瘤产品梯队逐渐丰富","url":"https://stock-news.laohu8.com/highlight/detail?id=2445204237","media":"金吾财讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445204237?lang=zh_cn&edition=full","pubTime":"2024-06-24 16:12","pubTimestamp":1719216733,"startTime":"0","endTime":"0","summary":"非肿瘤领域：PCSK9单抗在2023年6月审报国内NDA，IL12/23单抗在2023年8月审报NDA，预计2024年内两个品种有望获批上市，IL17单抗治疗银屑病在2023年12月已达有效性终点，完成安全性随访后即将报产。该行预计公司2024-2026年营收分别为24.73/37.43/55.81亿元，采用分部估值法，康方生物总计估值343亿元，取1人民币=1.1港元，总计估值377亿港元，首次覆盖，给予“买入”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/ZDcxODE0MDcxNDc0MDg4MTY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDcxODE0MDcxNDc0MDg4MTY=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1939190","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","600918"],"gpt_icon":0},{"id":"2445048978","title":"出海创新仍为主线，港股创新药ETF(159567)跟踪指数趋势上行，康方生物、药明生物、亚盛医药-B领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2445048978","media":"有连云","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445048978?lang=zh_cn&edition=full","pubTime":"2024-06-24 14:41","pubTimestamp":1719211305,"startTime":"0","endTime":"0","summary":"2024年6月24日，港股创新药板块趋势上行。盘面上，康方生物领涨，药明生物、亚盛医药-B跟涨，港股创新药ETF市场热度较高，过去5个交易日日均成交额达到6194万元。国内医药创新支持政策陆续出台，叠加美债利率下行预期，创新产业链有望迎来估值修复。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241441469f5e99dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241441469f5e99dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09926","LU2039709279.SGD","LU0456827905.SGD","BK1576","LU0307460666.USD","LU0181495838.USD","SG9999002463.SGD","LU0052750758.USD","LU0320764599.SGD","LU0417516902.SGD","LU0979878070.USD","LU0708995583.HKD","LU0819121731.USD","BK1141","LU0326950275.SGD","LU0856984785.SGD","LU1794554557.SGD","LU0359202008.SGD","02269","LU0051755006.USD","IE00B543WZ88.USD","LU0417516571.SGD","BK1610","BK1589","BK1574","LU1242518931.SGD","LU0516423174.USD","LU1242518857.USD","LU1720050803.USD","LU0327786744.USD","LU0516423091.SGD","LU0348735423.USD","LU1880383366.USD","09939","LU0516422440.USD","LU0516422952.EUR","LU0823426480.USD","LU1688375341.USD","IE00B0JY6N72.USD","IE00B5MMRT66.SGD","BK1161","LU0043850808.USD","LU0823426308.USD","SG9999002562.SGD","LU0348783233.USD","BK1521","LU0348825331.USD","BK1515","LU0572944931.SGD","06855"],"gpt_icon":0},{"id":"2445090050","title":"康方生物(09926)上涨5.05%，报37.45元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2445090050","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445090050?lang=zh_cn&edition=full","pubTime":"2024-06-24 11:04","pubTimestamp":1719198256,"startTime":"0","endTime":"0","summary":"6月24日，康方生物盘中上涨5.05%，截至11:04，报37.45元/股，成交1.56亿元。康方生物科技(开曼)有限公司是一家专注于研究、开发、生产和商业化全球病人可负担的创新抗体新药的生物制药公司，拥有独特的研发创新体系、国际化标准的GMP生产体系和先进的商业化体系。截至2023年年报，康方生物营业总收入45.26亿元、净利润20.28亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/06/24110441157825.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU0348784397.USD","09926","BK1574","LU0348783233.USD","IE00B543WZ88.USD","LU0417516571.SGD","BK1161","IE00B5MMRT66.SGD","LU1720050803.USD","LU1794554557.SGD"],"gpt_icon":0},{"id":"2445401897","title":"康方生物盘中异动 早盘股价大涨5.05%报37.451港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2445401897","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445401897?lang=zh_cn&edition=full","pubTime":"2024-06-24 11:04","pubTimestamp":1719198250,"startTime":"0","endTime":"0","summary":"2024年06月24日早盘11时04分，康方生物股票出现异动，股价急速上涨5.05%。截至发稿，该股报37.451港元/股，成交量423.679万股，换手率0.49%，振幅6.31%。资金方面，该股资金流入7643.44万港元，流出5795.07万港元。康方生物股票所在的生物技术行业中，整体涨幅为0.04%。其相关个股中，康方生物、嘉和生物-B、再鼎医药涨幅较大，振幅较大的相关个股有方达控股、歌礼制药-B、圣诺医药-B，振幅分别为15.38%、8.89%、8.74%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241104119681623c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241104119681623c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0348784397.USD","LU1794554557.SGD","LU0348783233.USD","LU1720050803.USD","BK1574","IE00B543WZ88.USD","IE00B5MMRT66.SGD","BK1161","09926","LU0417516571.SGD"],"gpt_icon":0},{"id":"2445097013","title":"康方生物早盘涨逾4% 获国信证券维持“优于大市”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2445097013","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445097013?lang=zh_cn&edition=full","pubTime":"2024-06-24 10:44","pubTimestamp":1719197040,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　康方生物（09926）早盘上涨3.79%，现报37港元，成交额1.23亿港元。\n　　近日，国信证券发布研究报告称，维持康方生物（09926）“优于大市”评级，看好AK112获批上市后在中国的销售放量，以及在全球的临床推进和后续的数据读出。维持康方生物的盈利预测，预计2024-26年公司营收为25.54/42.03/64.36亿元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-24/doc-inazuxrm0899209.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-24/doc-inazuxrm0899209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09926","002736"],"gpt_icon":0},{"id":"2445092581","title":"【港股通】康方生物(09926)逆市涨3.79% 依达方获药监局批准新药上市申请 麦格理升其目标价14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2445092581","media":"金吾资讯","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445092581?lang=zh_cn&edition=full","pubTime":"2024-06-24 10:26","pubTimestamp":1719196012,"startTime":"0","endTime":"0","summary":"金吾财讯 | 康方生物(09926)早盘股价逆市上扬，截至发稿，报37港元，涨3.79%，成交额9731.83万刚玉按。消息面上，麦格理表示，依达方获药监局批准新药上市申请，且依达方在III期单药“头对头”临床研究中疗效显著优于帕博利珠单抗的药物，创造了历史。该行将公司2024至2026财年收入预测分别上调13%、20%及20%，基本纯利预测分别上调24%、83%及250%。将目标价上调14%至64元，以反映以上积极的临床数据和在内地获批新药上市申请。予“跑赢大市”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062410270995d0b156&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062410270995d0b156&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSTECH","09926","HSCEI","07226"],"gpt_icon":0},{"id":"2445909258","title":"高质量国产创新药出海事件再临！港股创新药ETF(159567)跟踪指数趋势上行，康方生物、康希诺生物、再鼎医药领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2445909258","media":"有连云","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445909258?lang=zh_cn&edition=full","pubTime":"2024-06-24 10:21","pubTimestamp":1719195716,"startTime":"0","endTime":"0","summary":"2024年6月24日，港股创新药板块趋势上行。盘面上，康方生物领涨，康希诺生物、再鼎医药跟涨，港股创新药ETF市场热度较高，过去5个交易日日均成交额达到6194万元。伴随我国药企创新实力的逐步提升，以呋喹替尼为代表的我国高质量国产创新药出海正当时，可重点围绕景气度边际转暖的赛道的优质公司进行布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241021589f5de898&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406241021589f5de898&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","ZLAB","LU0348784397.USD","09926","LU0348783233.USD","LU1720050803.USD","LU1794554557.SGD","BK1161","BK1515","IE00B543WZ88.USD","LU0417516571.SGD","BK1191","688185","BK1588","BK1574","06185","IE00B5MMRT66.SGD","09688"],"gpt_icon":0},{"id":"2445094658","title":"港股异动 | 康方生物(09926)再涨超4% 卡度尼利单抗降价超五成 依达方III期临床研究疗效显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2445094658","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445094658?lang=zh_cn&edition=full","pubTime":"2024-06-24 10:11","pubTimestamp":1719195095,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物再涨超4%，截至发稿，涨3.93%，报37.05港元，成交额7536.65万港元。消息面上，近日，据行业媒体医药魔方的报道，2024年国家医保谈判进入准备阶段之际，康方生物下调了其双抗新药卡度尼利单抗 的价格。同日，康方生物向界面新闻确认了这一价格且取消赠药，称这一价格将给予患者购药更大灵活性，并表示将积极参加今年医保谈判。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","HSCEI","LU0417516571.SGD","HSTECH","07226","BK1161","LU0348783233.USD","BK4134","09926","BK1574","III","LU1720050803.USD","YANG","LU0348784397.USD","IE00B543WZ88.USD","LU1794554557.SGD"],"gpt_icon":0},{"id":"1114706690","title":"港股异动 | 康方生物逆市涨超4%，卡度尼利年内或进医保","url":"https://stock-news.laohu8.com/highlight/detail?id=1114706690","media":"老虎资讯综合","labels":["movement"],"top":-1,"share":"https://www.laohu8.com/m/news/1114706690?lang=zh_cn&edition=full","pubTime":"2024-06-24 10:03","pubTimestamp":1719194593,"startTime":"0","endTime":"0","summary":"6月24日， 康方生物逆市涨超4%，截至发稿，涨3.93%，报37.05港元。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926"],"gpt_icon":0},{"id":"2445050542","title":"港股异动 | 康方生物(09926)逆市涨超3% 卡度尼利降价并取消赠药 市场憧憬今年进医保","url":"https://stock-news.laohu8.com/highlight/detail?id=2445050542","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445050542?lang=zh_cn&edition=full","pubTime":"2024-06-21 10:55","pubTimestamp":1718938510,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康方生物逆市涨超3%，截至发稿，涨2.54%，报36.4港元，成交额8796.8万港元。康方生物企业人员透露，卡度尼利在此时降价和取消赠药，确系为2024年的医保国谈做准备。有医药研究员表示，降价与取消赠药相互抵消，预计对产品销售影响有限；卡度尼利单抗在今年进医保不是大问题。此外，国信证券发布研究报告称，维持康方生物“优于大市”评级，看好AK112获批上市后在中国的销售放量，以及在全球的临床推进和后续的数据读出。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1138439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09926","BK1161","HSCEI","07226","BK1574","HSTECH","LU1720050803.USD","YANG","LU0348784397.USD","LU1794554557.SGD","LU0417516571.SGD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU0348783233.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akesobio.com","stockEarnings":[{"period":"1week","weight":-0.0288},{"period":"1month","weight":-0.1557},{"period":"3month","weight":-0.1853},{"period":"6month","weight":-0.1781},{"period":"1year","weight":0.0262},{"period":"ytd","weight":-0.1994}],"compareEarnings":[{"period":"1week","weight":-0.0168},{"period":"1month","weight":-0.0172},{"period":"3month","weight":0.0624},{"period":"6month","weight":0.0675},{"period":"1year","weight":-0.0796},{"period":"ytd","weight":0.0423}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康方生物科技（开曼）有限公司是一家主要从事生物产品研发的投资控股公司。该公司专注于满足肿瘤、免疫及其他治疗领域在全球的未决医疗需求。该公司的主要产品包括AK104、AK105、AK112及AK109。该公司于中国市场及海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.000127},{"month":2,"riseRate":0.25,"avgChangeRate":-0.01324},{"month":3,"riseRate":0.25,"avgChangeRate":-0.055315},{"month":4,"riseRate":0.75,"avgChangeRate":0.01855},{"month":5,"riseRate":0.4,"avgChangeRate":0.001922},{"month":6,"riseRate":0.6,"avgChangeRate":0.140431},{"month":7,"riseRate":0.2,"avgChangeRate":-0.058114},{"month":8,"riseRate":0.25,"avgChangeRate":-0.053599},{"month":9,"riseRate":0.5,"avgChangeRate":-0.021692},{"month":10,"riseRate":0.75,"avgChangeRate":0.139401},{"month":11,"riseRate":1,"avgChangeRate":0.091362},{"month":12,"riseRate":0.5,"avgChangeRate":0.104965}],"exchange":"SEHK","name":"康方生物","nameEN":"AKESO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康方生物,09926,康方生物股票,康方生物股票老虎,康方生物股票老虎国际,康方生物行情,康方生物股票行情,康方生物股价,康方生物股市,康方生物股票价格,康方生物股票交易,康方生物股票购买,康方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康方生物(09926)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康方生物(09926)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}